A recent NITI Aayog report highlights that India’s pharmaceutical supply chain remains heavily vulnerable, relying on Chinese imports for 65% of its critical active pharmaceutical ingredients (APIs) and key starting materials. To counter global pressures, including a proposed 12.5% US tariff under Section 301 regarding forced labour safeguards, Indian manufacturers across solar, textile, and steel sectors are rapidly implementing private supply-chain audits and rigorous origin-traceability frameworks. Meanwhile, global trade flows have experienced a massive reorientation; due to West Asian geopolitical disruptions, Singapore has overtaken China as a primary export destination, with a sharp spike in Indian petroleum product volumes. On a positive note for domestic agriculture, the reopening of the Strait of Hormuz and eased export restrictions from China have caused global urea prices to crash by 55–60% to around $415–420 per tonne. This dramatic price drop is expected to cap the government’s fiscal year 2027 fertilizer subsidy budget at ₹2.5 lakh crore, down significantly from earlier conflict-driven projections.